Search results
Showing results for
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Emmanouil Solomonidis
Emmanouil Solomonidis - Postdoctoral Research Assistant
Romila Moirangthem
Romila Moirangthem - Postdoctoral Research Assistant in Immunology
Cynthia Srikesavan
PT PhD Cynthia Srikesavan - Senior Researcher in Physiotherapy
Shivani Kanabar
Shivani Kanabar - NIHR Academic Clinical Fellow in Respiratory Medicine
David Keene
BSc (Hons) MSc DPhil MCSP MMACP David Keene - Kadoorie Professor of Trauma Rehabilitation
Srinivasa Rao Rao
MBBS, MS (res), DPhil, AFHEA Srinivasa Rao Rao - Senior Researcher in Cancer Genomics
Claudia Monaco
Claudia Monaco - Professor of Cardiovascular Inflammation
Ed Burn
Ed Burn - Senior Researcher in Epidemiology and Health Economics
Fernando Martinez Estrada
Fernando Martinez Estrada - Honorary Departmental Senior Research Associate
Kirsten Leyland
BA, MSc, DPhil Kirsten Leyland - HONORARY Postdoctoral Epidemiologist
Nasim Zargar
Nasim Zargar - Honorary Departmental Product Development Scientist and Senior Production Manager